Editorial Videos

Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for gastric cancers.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab, identifies advertising/marketing trends he expects in Q1 of 2025.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explains how the healthcare industry's experience with privacy-compliant targeting can serve as a roadmap for other sectors.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the potential implications of the phase-out of cookies for the broader advertising industry.

Ron Lanton, Partner, Lanton Law, discusses the legal implications of the FDA’s broad label challenge to PD-1 inhibitors for gastric cancers.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discusses the need to balance personalized targeting with the ethical imperative to protect consumer privacy.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explores the most promising alternative targeting methods that advertisers can adopt in a post-cookie world, and how they compare to traditional approaches.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discussed how the use of Real-World Data has evolved in the healthcare industry in terms of privacy and targeting effectiveness.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored how healthcare advertisers have been able to effectively target patients without relying heavily on traditional tracking methods.

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explore the potential long-term implications of the ongoing drug shortages for the healthcare system and patient care.

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explain how the regulatory framework for compounded medications can be further strengthened to ensure quality and safety, while still maintaining flexibility to address patient needs.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, explains how to identify a compound pharmacy versus and illicit actor.

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss how compounded medications differ from commercially available drugs in terms of their manufacturing process, quality standards, and more.

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss specific challenges that have arisen in the supply chain for semaglutide and how to ensure that patients continue to have access to essential medications, particularly during shortages.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member identifies marketing trends you expect to be big right away in 2025.

In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how personalized audio will be utilized within the pharma marketing industry in 2025.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs effectively measure the return on investment (ROI) of their marketing efforts in the pharmaceutical industry, particularly in light of the long-term nature of drug development and approval processes.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member explains how pharmaceutical companies can effectively navigate the evolving regulatory landscape and ensure that their marketing activities comply with ethical standards and industry best practices.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how pharmaceutical companies can effectively balance personalized marketing efforts with maintaining data privacy and ensuring patient trust.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses integrating digital solutions with traceability and drug administration.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses ways that digital passports can help ensure patients receive the correct medication.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses innovations in label design that could lead to improved patient outcomes and less medical errors.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses scenarios where unclear labeling led to challenges for patient outcomes.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses ways to ensure that product labels are easily understood universally.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses issues faced by the pharmaceutical industry when it comes to proper drug labeling.

In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, explains how can companies position themselves to attract VC/federal funding, and identifies potential regulatory and policy implications of these trends.